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Abstract
Introduction Clinical guidelines have recommended a
1-year trastuzumab regimen as standard care for early
human epidermal growth factor receptor 2 (HER2)-positive
breast cancer; however, this recommendation can have a
dramatic impact on total drug expenditures in middle-in-
come countries (MICs). We performed a cost-effectiveness
analysis from the Iranian healthcare perspective to find an
optimum duration of trastuzumab use in Iran.
Method We compared four treatment strategies comprising
chemotherapy and varying durations of trastuzumab use
(no trastuzumab, 6, 9 months, and 1 year), and a Markov
model and probabilistic sensitivity analysis were used to
estimate the costs and effects of the strategies. We then
examined the cost effectiveness of the strategies at differ-
ent willingness-to-pay (WTP) thresholds and ages at onset
of treatment.
Results Incremental costs (versus no trastuzumab) were
€8826 (6 months), €13,808 (9 months) and €18,588
(12 months), while incremental quality-adjusted life-years
(QALYs) were 0.65 (6 months), 0.87 (9 months) and 1.14
(12 months). At a threshold of 3 9 gross domestic product
(GDP)/capita (€21,000/QALY) and for patients younger
than 59 years, the 6-month protocol was most likely to be
cost effective (probability of 42%). At a threshold of
4 9 GDP/capita (€28,000/QALY), the 6-month and 1-year
regimens were essentially equal in cost effectiveness (37
and 35%, respectively). At this WTP threshold, the
6-month and 1-year regimens were optimal strategies only
for patients up to 66 and 44 years of age, respectively.
Conclusion In contrast to clinical guidelines, 6 months of
trastuzumab may be the most cost-effective option for Iran.
The lower absolute WTP threshold and lower life expec-
tancy compared with high-income countries are two crucial
parameters in the cost effectiveness of interventions in
MICs. It is therefore necessary to strike a balance between
maximum population health and maintaining affordability
in these countries.
Key Points for Decision Makers
Lower absolute willingness-to-pay and life
expectancy are two important issues that can affect
conclusions regarding the cost effectiveness of
treatment in middle-income countries
Although most clinical guidelines worldwide
recommend 1 year of trastuzumab for early human
epidermal growth factor receptor 2 (HER2)-positive
breast cancer, it is not the most cost-effective
strategy in Iran.
In Iran, the most cost-effective strategy is 6 months
of trastuzumab, but only for patients younger than 59
years of age.
A significant price reduction is necessary to make
trastuzumab cost effective for all patients.
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1 Introduction
Trastuzumab is a monoclonal antibody that is used in the
management of breast cancer (BC). It has mostly been used
as adjuvant treatment for patients in the early stage of BC
who overexpress human epidermal growth factor receptor 2
(HER2). Trastuzumab’s huge share of total drug expendi-
ture, particularly in middle-income countries (MICs), has
raised concerns among policymakers regarding efficient
resource allocation in their countries [1]. To date, 1 year of
trastuzumab use is considered as the optimum duration of
therapy for the adjuvant treatment of early-stage, HER2-
positive BC [2–4], based on the results of various ran-
domized controlled trials (RCTs).
As an MIC, Iran provided a national guideline that
recommends a 9-week period of trastuzumab use [5] due to
the unaffordability of 1 year of trastuzumab therapy [1];
however, clinical evidence suggests that very short dura-
tions of trastuzumab therapy cannot provide significant
efficacy [2]. Therefore, the main question in this regard is
‘‘What is the maximum obtainable level of health in an
MIC when we are dealing with an expensive
intervention?’’
The aim of this study was to provide a model-based
cost-effectiveness analysis (CEA) of adjuvant trastuzumab
for patients with early HER2-positive BC from an Iranian
healthcare perspective. Subsequently, we undertake a sce-
nario analysis to determine the optimum duration of tras-
tuzumab use in Iran.
2 Methods
In our study, we compared two treatment approaches
(chemotherapy with and without trastuzumab) for manag-
ing early HER2-positive BC. A Markov model was used to
estimate the marginal differences in clinical outcomes and
healthcare costs. We designed a cohort for patients with
HER2-positive BC and included the necessary information
in this model to estimate the incremental cost-effectiveness
ratio (ICER) of using trastuzumab for these patients with a
lifetime horizon in Iran. Afterward, a scenario analysis was
conducted to compare the cost effectiveness of different
strategies of trastuzumab therapy in an MIC.
2.1 Model Structure
We designed a model structure based on three sources of
information (Fig. 1). First, the routine practice of treating
HER2-positive BC in Iran was understood based on a
previous study of clinical practice using a claims database
and clinician survey [1]. We then discussed our interpre-
tations of the results through a number of interviews with
two Iranian academic oncologists, and based on our final
decision on data availability. The model was designed to be
able to compare two main arms (trastuzumab versus no
trastuzumab), and included six main health states: (1) early
BC; (2) loco-recurrence BC; (3) advanced BC; (4, 5) two
progression-free health states after treatment in early BC
and loco-recurrence BC; and (6) death. We also included
other health-state subgroups for loco-recurrence (loco-re-
gional and second primary BC), and advanced patients
(central nervous system [CNS], visceral, bone, and soft
tissue metastasis). Moreover, we incorporated long-term
cardiotoxicity in all states in which patients use trastuzu-
mab. A 3-month cycle length was used in the model [1].
In the model, patients with early HER2-positive BC
received chemotherapy with or without trastuzumab. After
treatment, patients moved to a follow-up state and could
progress to local or advanced BC. Patients stayed in the
follow-up state until the occurrence of progression (local or
distance recurrence) or second primary BC. We assumed
that patients in both arms were equally likely to receive all
Fig. 1 Summary model
structure. BC breast cancer,
HER2 human epidermal growth
factor receptor 2, CNS central
nervous system
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Table 1 Transition probabilities
Parameter Base-case
estimate
Distribution Distribution
parameters
Source
Trastuzumab effectiveness
DFS trastuzumab HR (12 m versus 0 m) 0.62 Log-normal l = -0.49,
r = 0.13
Moja et al. [2]
DFS trastuzumab HR (6 m versus 12 m) 1.28 Log-normal l = 0.23, r = 0.16 Pivot et al. [3]
DFS trastuzumab HR (9 m versus 12 m) 1.14 Log-normal l = 0.13, r = 0.08 Assumption
Treatment effect duration 48 m Log-normal l = 3.87,
r = 0.307
Hall et al. [10]
Disease progression
Recurrence without trastuzumab
Months 1–48 0.28 Beta a = 472, b = 1226 Gianni et al. [12]
Months 49–60 0.23 Beta a = 35, b = 116 Paik et al. [13]
Months 61–120 0.10 Beta a = 11, b = 94
Beyond 120 months 0 Fixed Expert opinion
Loco versus distant recurrences
Without trastuzumab 0.355 Beta a = 100, b = 182 Gianni et al. [12]
With trastuzumab 0.372 Beta a = 79, b = 133
Distance recurrence pattern
Without trastuzumab
Bone 0.25 Dirichlet a1 = 38 Piccart-Gebhart et al.
[16]Soft tissue 0.12 a2 = 19
Visceral 0.53 a3 = 82
CNS 0.10 a4 = 15
With trastuzumab
Bone 0.28 Dirichlet a1 = 24 Piccart-Gebhart et al.
[16]Soft tissue 0.07 a2 = 6
Visceral 0.40 a3 = 34
CNS 0.25 a4 = 21
Second primary or contralateral breast cancer
Years 1–4 0.019 Beta a = 33, b = 1698 Gianni et al. [12]
Years 5–10 0.026 Beta a = 10, b = 359 Metzger-Filho et al.
[48]
Increased risk of distant metastasis after local recurrence (HR)
Years 1–4 3.22 Log-normal l = 1.16, r = 0.14 Tanis et al. [17]
Years 5–10 6.14 Log-normal l = 1.68, r = 0.52
Cardiac toxicity
Trastuzumab-induced decline in LVEF 0.112 Beta a = 466, b = 4147 Moja et al. [2]
Trastuzumab-induced CHF 0.025 Beta a = 135, b = 5471
CHF due to chemotherapies 0.004 Beta a = 20, b = 4810
Duration of reversible cardiac toxicity 3 months Fixed Suter et al. [18]
Time of onset during treatment 3–6 months Dirichlet as = 8, 69, 14, 27
Population background level of CHF among Iranian females Age-specific Normal Talaei et al. [19]
Mortality
Background mortality for Iranian females Age specific Fixed NOfCR[20]
Breast cancer-specific mortality for Iranian females Age specific Fixed Vostakolaei et al. [7]
Mortality from heart failure for Iranian females (1 year, age-
adjusted)
0.263 Beta a = 727, b = 2042 Talaei et al. [19]
Mortality due to metastatic BC
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other medical services. Patients who had progressed to
loco-recurrence after receiving the treatment could move to
the disease-free state after the local-recurrence state, or
progress to advanced BC; patients who progressed to
advanced BC stayed there until they died from BC or other
causes. Some of the patients who received trastuzumab
developed reversible cardiac toxicity. Patients in all health
states could die due to background mortality.
2.2 Patient Characteristics
We set the age at onset of treatment at 45 years, in
accordance with the results of a variety of current claims
database [6] and epidemiological [7–9] studies in Iran.
2.3 Transition Probabilities
The following items describe the input parameters used in
the model as well as their sources. Various transition
probabilities used in the model are shown in Table 1.
2.3.1 Treatment Effect
The effectiveness of trastuzumab was derived from a
Cochrane review [2] that was a comprehensive systematic
review and meta-analysis of eight RCTs regarding disease-
free survival (DFS) of trastuzumab. Due to our study
design, we relied on a DFS hazard ratio (HR) based on the
results of the meta-analysis of those trials (five of eight)
that investigated the effects of more than 6 months of
trastuzumab therapy. To include the treatment effect
duration in the model, we used an assumption that was used
in a CEA of trastuzumab in the UK [10], based on dis-
cussions with experts.
2.3.2 Cancer Progression
For the first 4 years, the recurrence rate in the ‘no trastuzu-
mab’ arm was obtained from the latest HERceptin Adjuvant
(HERA) trial [11] report after a 4-year patient follow-up
[12]. For years 5–10, the recurrence rateswere taken from the
anthracycline-treated HER2-positive subgroup of the
National Surgical Adjuvant Breast and Bowel Project
(NSABP) protocol B-15 trial [13]. Since that trial only
focused on lymph node-positive patients, we applied a rel-
ative risk of 0.815 based on a study reporting that 63% of
Iranian patients have node-positive BC at the time of diag-
nosis [14], and the assumption that node-positive patients
have a recurrence rate that is two times greater than node-
negative patients [15]. We also assumed no chance of
recurrence after 10 years based on expert opinion. The ratio
of loco-recurrences to distant recurrences was obtained from
the results of the HERA trial [16]. Two HRs were applied to
represent the increased risk of distant metastases after local
recurrence. These HRs were 3.22 (95% confidence interval
[CI] 2.02–6.55) and 6.14 (95% CI 2.02–6.55) for years 1–4
and 5–10, respectively [17].
2.3.3 Cardiac Toxicity
The results of a Cochrane systematic review and meta-
analysis [2] were used to estimate the probabilities of
decline in left ventricular ejection fraction (LVEF) and
congestive heart failure (CHF) occurring during 1 year of
trastuzumab therapy and other chemotherapy drugs. The
time of onset and toxicity duration for patients who had
reversible cardiac toxicity were taken from the HERA trial
[18]. Moreover, patients suffer from CHF based on an age-
specific background, and these probabilities were obtained
from a cohort study of 6504 individuals in one province of
Iran [19].
2.3.4 Mortality
Age-specific background mortality rates were obtained
from online data of the National Organization for Civil
Registration (NOCR) [20], which included data on all
causes of death in Iran. We used another study of BC
mortality rates in three different age ranges [7] to subtract
the BC mortality rate from the NOCR data. Data on the
age-specific CHF mortality rate in Iran was obtained from
an Iranian cohort study [19]. Other parameters regarding
BC mortality rates in various metastatic states were
extracted from international studies.
Table 1 continued
Parameter Base-case
estimate
Distribution Distribution
parameters
Source
Bone (over 5 years) 0.63 Beta a = 17, b = 10 Dawood et al. [49]
Soft tissue (over 5 years) 0.77 Beta a = 12, b = 4
Visceral (over 5 years) 0.78 Beta a = 28, b = 8
Brain (over 9 months) 0.50 Beta a = 54, b = 54 Niwinska et al. [50]
CHF congestive heart failure, DFS disease-free survival, LVEF left ventricular ejection fraction, m months, HR hazard ratio, CNS central nervous
system, BC breast cancer
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2.4 Outcomes
Life-years (LYs) and quality-adjusted life-years (QALYs)
were estimated for both arms. Table 2 shows the utility
values used in this study. We used the results of a study
that provided the utility weights for various health states,
based on the EQ-5D questionnaire in Sweden [21]. Another
study that used the EQ-5D was selected to find the utility
weight for patients who suffer from symptomatic heart
failure in the UK [22]. Finally, the utility value (EQ-5D)
for patients with brain metastases was obtained from a
CEA study in the UK [10].
2.5 Costs
Direct medical costs were calculated from an Iranian
healthcare perspective. We assumed 100% coverage for all
healthcare services by payers, which helps policymakers to
examine the cost effectiveness of complete coverage of all
services. We used a recent study that investigated health-
care costs and resource use in both the public and private
sectors in Iran, which covers approximately 50% of all
Iranians (approximately 40 million) [6]. Due to the variety
of health insurance coverage in Iran [23], out-of-pocket
payments had already been included in cost calculations
[6]; therefore, the costs shown in Table 2 comprise the total
costs of medical services. The average patient weight must
be known to calculate the cost of trastuzumab; therefore,
we used data from a 3-year observational period [1] to
estimate the average weight based on the average dose of
trastuzumab per patient using trastuzumab. The average
dose per patient per prescription was 420 mg (95% CI
415–424; n = 1295), which corresponds with an average
weight of 70 kg (69–71). While this may not represent the
true average weight of the patients, in reality these real-
world data represent the total amounts of trastuzumab, both
used and wasted. Patients received trastuzumab in a 3-week
cycle until the end of therapy.
Table 2 Utilities and costs (year 2017)
Parameter Mean Standard error Distribution Source
Health utilities
Baseline (disease-free) 0.779 0.017 Beta Lidgren et al. [21]
Treatment of early stage 0.779 0.017 Beta Assumption
Symptomatic cardiac toxicity 0.600 0.010 Beta Calvert et al. [22]
Loco-recurrence 0.780 0.040 Beta Lidgren et al. [21]
Second primary breast cancer (first year) 0.700 0.032 Beta
Advanced (bone, visceral and soft tissue) 0.690 0.033 Beta
Advanced (brain) 0.600 0.120 Beta Hall et al. [10]
Costs (€) [€1 = 34,000 rilas]
Treatment
Trastuzumab (first cycle) 6123 Fixed SSO [51]
Trastuzumab (second, third, and fourth cycles) 5623 Fixed
Early treatment first year 3689 245 Log-normal Ansaripour et al. [6]
Trastuzumab administration (6 months)a 188 194 Log-normal
Trastuzumab administration (9 months)a 329 359 Log-normal
Trastuzumab administration (1 year)a 471 485 Log-normal
Follow-up annual cost 370 34 Log-normal
Cardiac toxicity
Symptomatic heart failure annual cost 584 140 Log-normal Ansaripour et al. [6]
Cancer recurrence costs
Second primary breast cancer first year 6024 228 Log-normal Ansaripour et al. [6]
Second primary breast cancer annual cost As follow-up annual cost Log-normal Assumption
Loco-recurrence first year 3922 177 Log-normal Ansaripour et al. [6]
Loco-recurrence annual cost 2238 357 Log-normal
Advanced treatment first year 18,151 1394 Log-normal
Advanced treatment annual cost 83,249 2027 Log-normal
a The cost of trastuzumab administration in the first 9 weeks is excluded here due to administration of trastuzumab with other chemotherapy
drugs in the same sessions. The cost of trastuzumab administration in the first 9 weeks is included in the cost of early treatment in the first year
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The annual national healthcare tariff [24] was used to
inflate or adjust the costs attained from years other than the
2014–2017 values.
2.6 Analysis
In the absence of a national guideline for economic eval-
uations in Iran, both costs and effects were discounted by
3.5% per annum, as suggested by the World Health
Organization’s Choosing Interventions that are cost-effec-
tive (WHO-CHOICE) project [25]. A half-cycle correction
was also applied.
The influence of specific input parameters on the ICER
of CEA was examined using deterministic sensitivity
analysis (DSA). The ranges in values were determined
based on either the literature or on expert opinion.
A probabilistic sensitivity analysis (PSA) was performed
in order to quantify the overall uncertainty in the expected
output measures [26, 27]. The log-normal distribution was
applied for relative risks, HRs, and costs, while the
Dirichlet distribution was used for multinomial proportions
and the beta distribution was used for binomial proportions
and utility weights. The analysis used 10,000 iterations
obtained via Markov Chain Monte Carlo simulation.
Based on the WHO-CHOICE, the willingness-to-pay
(WTP) threshold in Iran would be 3 9 gross domestic
product (GDP)/capita, which is equal to €21,000 per
QALY (€1 = 34,000 rials) [28]. Because widespread
international economic sanctions on Iran began in 2012, we
used GDP per capita in 2011, as reported by the World
Bank [29], to avoid the effects of these sanctions on Iran’s
GDP.
The building of the model, calculations, and statistical
analysis were performed using R software for Microsoft
Windows, version 3.2.2 (The R Project, Vienna, Austria)
[30].
2.7 Estimation of the Optimum Duration
and Maximum Age Threshold for Trastuzumab
Use
Three scenarios of 6, 9 months, and 1 year of trastuzumab
use were designed to compare their cost effectiveness. We
used the results of the randomized, non-inferiority PHARE
trial [3], which compared 6 months versus 1 year of
adjuvant trastuzumab therapy, and the results of a
Cochrane meta-analysis [2], which compared 1 year of
trastuzumab versus no trastuzumab therapy. For 9 months
of trastuzumab use, we assumed that the effectiveness HR
was half of the non-inferiority HR in the PHARE trial
(Table 1). The ICERs of the three strategies were calcu-
lated and, eventually, their probability of being cost
effective was compared with that of the no trastuzumab
arm. Furthermore, due to the importance of patient age, we
investigated how the age threshold for treatment can affect
the optimal duration of trastuzumab use. Multiple PSAs
were performed, with various ages (40–70 years) as the age
at onset of treatment, to determine the ‘maximum age
threshold’ for the best-case scenario. The ‘maximum age
threshold’ represents the maximum age at the onset of
treatment that still results in the strategy being optimal,
versus other strategies included in the comparison at a
particular WTP threshold.
2.8 Model Validation
Internal validation was performed to assess how well the
model’s results for DFS and overall survival (OS) corre-
sponded with the no trastuzumab and 1-year trastuzumab
arms from the HERA trial. Similarly, the results of the
PHARE trial were used to validate the model’s results for
the 1-year and 6-month trastuzumab strategies.
3 Results
Over a lifetime horizon, all trastuzumab strategies were
cost effective versus no trastuzumab at a WTP of 3 9 GDP
(Fig. 2). The results of CEA, reported in Table 3, show that
at the WTP threshold of 3 9 GDP, and a 42% probability,
the 6-month protocol was the most cost-effective strategy,
Fig. 2 Cost-effectiveness plan for trastuzumab use scenarios versus
no trastuzumab (a sample of 7000 results of PSA for every strategy).
The ellipses represent 95% confidence intervals. GDP gross domestic
product, QALYs quality-adjusted life-years, PSA probabilistic sensi-
tivity analysis
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while other strategies showed lower rates of being cost
effective. The acceptability curves representing the prob-
abilities that various strategies are cost effective across
various WTP thresholds in the base-case scenario can be
found in Fig. 3. The 1-year trastuzumab strategy was cost
effective in only 21% of simulations, and the 9-month and
no trastuzumab strategies were cost effective in 21 and
17% of cases, respectively. When the WTP threshold was
increased to 4 9 GDP, the 6-month and 1-year regimens
were essentially equal in cost effectiveness (37 and 35%,
respectively). The 9-month regimen had a 20% probability
of cost effectiveness. However, the chance of the no tras-
tuzumab strategy being cost effective fell to 8% when a
WTP threshold of 4 9 GDP was applied.
The base-case and DSA of the model yields ICERs for
6, 9 months and 1 year of €15,108, €16,800, and €17,086
per QALY versus no trastuzumab, respectively. Subse-
quently, deterministic one-way sensitivity analysis (sum-
marized in Table 4) revealed that the key drivers were the
acquisition cost and clinical effectiveness of 1 year of
trastuzumab use versus no trastuzumab. Additionally,
probabilistic one-way sensitivity analysis showed that
when the cost of trastuzumab was changed from -30 to
?30% in the base-case, the probability of the 1-year reg-
imen being cost effective decreased from 41 to 8% (Online
Resource 1). However, 6 months of trastuzumab therapy
showed less of a change (9; 34–43%) at a threshold of
3 9 GDP. In contrast, changes in the HR of DFS for
6 months of trastuzumab use versus no trastuzumab
showed a range of 16% (54–38%) in the lower (0.50) and
upper (0.74) limits (Online Resource 2). At a threshold of
3 9 GDP, the 6-month regimen was the most cost-effec-
tive strategy (54%) for the lower limit of HR, and the no
trastuzumab strategy was the cost-effective strategy for the
upper limit of HR. Finally, our results (Fig. 4) show that
the 6-month strategy is only cost effective when treated
patients are not older than 59 years (the maximum age
threshold). At this age, and at a WTP threshold of
3 9 GDP, the two strategies of 6 months of trastuzumab
and no trastuzumab had almost equal chances of being cost
effective (39.5 versus 40%, respectively). However, this
age threshold can change if the WTP is increased or
decreased. At the WTP threshold of 4 9 GDP, 1 year of
trastuzumab use is only cost effective for patients who are
younger than 44 years, and 6 months of trastuzumab use
may be the best strategy for patients between 44 and 66
years of age (Online Resource 3). Finally, the impact of
various ages (40–70 years) on the cost effectiveness of
different strategies are shown in Online Resource 4.
Figure 5 illustrates the effect of price reductions on the
maximum age threshold. Our analyses revealed that tras-
tuzumab is only cost effective if the price was to be
Table 3 Results of the cost-
effectiveness analysis
Strategies Cost (€) QALYs LYs ICER (QALY) ICER (LY)
No trastuzumab 14,541 11.1 14.41 NA NA
6 months of trastuzumab 22,442 11.71 15.18 14,625 11,664
D = 8901 D = 0.61 D = 0.76
9 months of trastuzumab 28,410 11.95 15.48 16,370 13,037
D = 13,869 D = 0.85 D = 1.06
1 year of trastuzumab 33,160 12.22 15.82 16,695 13,279
D = 18,619 D = 1.12 D = 1.40
D = incremental values for costs and effectiveness of trastuzumab therapy strategists versus no trastuzumab
QALYs quality-adjusted life-years, LYs life-years, ICER incremental cost-effectiveness ratio, NA not
applicable
Fig. 3 Acceptability curves of the base-case scenario. GDP gross
domestic product
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reduced by 30%; however, this reduction would make
1 year of trastuzumab use the optimal strategy only if it
was given to patients younger than 49.5 years of age. As
Fig. 5 shows, a 10% reduction in price increases the
maximum age threshold by 3 and 6 years for the 6-month
and 1-year treatment regimens, respectively.
The internal validation results for the three strategies,
including no trastuzumab and 1 year and 6 months of
trastuzumab use revealed no significant differences
between the results of the model and the results of the trials
used to perform this study (Table 5).
4 Discussion
The use of monoclonal antibodies such as trastuzumab is a
hotly debated topic among policymakers, patients, and
healthcare professionals in MICs due to their considerable
Table 4 Results of one-way deterministic sensitivity analysis; the impact of the top seven key drivers on the incremental cost-effectiveness ratio
Base-case Limits Value Reference Strategies
No trastuzumab 6-month trastuzumab 9-month trastuzumab 1-year trastuzumab
Cost
changes
QALY
changes
LY
changes
Cost/
QALYs
changes
Cost/LY
changes
Cost/
QALYs
changes
Cost/LY
changes
Cost/
QALYs
changes
Cost/LY
changes
Base-case Mean 14,541 11.1 14.4 14,625 11,664 16,370 13,037 16,695 13,279
Cost of
trastuzumab
Lower -30% 9135 7285 10,542 8395 10,884 8658
-38% -38% -36% -36% -35% -35%
Upper ?30% 20,116 16,043 22,198 17,678 22,505 17,901
38% 38% 36% 36% 35% 35%
Effectiveness of
trastuzumab
Disease-free
survival HR
12 m versus 0 m
Lower 0.50 7496 5974 10,338 8232 12,079 9610
-49% -49% -37% -37% -28% -28%
Upper 0.74 62,873 50,398 33,618 26,778 25,740 20,464
330% 332% 105% 105% 54% 54%
Effectiveness of
trastuzumab
Disease-free
survival HR
12 m versus 6 m
Lower 1.20 11,377 9070
-22% -22%
Upper 1.36 19,924 15,899
36% 36%
Effectiveness of
trastuzumab
Disease-free
survival HR
12 versus 9 m
Lower 1.09 14,526 11,568
-11% -11%
Upper 1.18 18,164 14,465
11% 11%
Age at start Lower 40 14,688 11.7 15.2 13,352 10,630 14,994 11,921 15,322 12,169
1% 6% 6% -9% -9% -8% -9% -8% -8%
Upper 50 14,336 10.4 13.5 16,425 13,130 18,307 14,611 18,619 14,840
-1% -7% -7% 12% 13% 12% 12% 11% 12%
Discount rate
for costs
Lower 0% 17,612 13,497 10,764 15,485 12,332 15,963 12,698
21% -8% -8% -5% -5% -4% -4%
Upper 7% 12,624 15,317 12,216 16,932 13,484 17,174 13,660
-13% 5% 5% 3% 3% 3% 3%
Discount rate
for effectiveness
Lower 0% 18.4 23.9 7335 5791 8283 6534 8499 6699
66% 66% -50% -50% -49% -50% -49% -50%
Upper 7% 7.8 10.1 25,341 20,431 28,088 22,599 28,455 22,854
-30% -30% 73% 75% 72% 73% 70% 72%
Blank spaces indicate no effects on the results of the base-case scenario
LY life-years, M month, QALYs quality-adjusted life-years, HR hazard ratio
A. Ansaripour et al.
impact on the healthcare budgets of these nations. For
example, in Iran, trastuzumab alone accounts for approxi-
mately €93–140 million (approximately 4–6%) of total
pharmaceutical expenditure [1]. Trastuzumab is an
effective but very expensive drug for patients with HER2-
positive BC; therefore, policymakers in MICs can neither
ignore it because of its effectiveness nor reimburse it with
the same duration, as clinical guidelines have recom-
mended in high-income countries (HICs), due to its cost.
Specifically, more money spent on trastuzumab means less
money for other treatments [31]. The questions that
healthcare professionals and policymakers in these coun-
tries must answer include: ‘‘What is the optimum duration
of trastuzumab use to provide an efficient and affordable
treatment?’’ and ‘‘How can we balance population health
and affordability?’’ In response to these questions, our
study provides valuable information regarding the cost
effectiveness of various trastuzumab strategies in Iran,
which may also be useful for other MICs. Moreover, to our
knowledge this is the first CEA that examines age hetero-
geneity of patients and explores the impact of life expec-
tancy on the cost effectiveness of various trastuzumab
strategies in an MIC.
The effectiveness of shorter durations of trastuzumab
therapy has been studied in various RCTs. The FinHER
(Finland Herceptin) trial [32] investigated clinical out-
comes in 9 weeks of trastuzumab use and reported an HR
of 0.42 (95% CI 0.21–0.83, p = 0.01) for the DFS of
trastuzumab use versus no trastuzumab. However, this
study was faced with some limitations, such as small
sample size, and the results of other trials (SOLD [33] and
SHORT-HER [34]) that also focused on 9-week trastuzu-
mab use have not yet published. As a result, we therefore
excluded the 9-week strategy as a comparator in this study.
The clinical outcomes of 6 months of trastuzumab use were
the subject of two RCTs (PHARE [3] and PERSEPHONE
[35]). Since only the results of PHARE are currently
available, we used the PHARE results in this study. Our
assumption regarding the DFS HR in the 9-month strategy
was not supported by a real RCT. It was therefore neces-
sary to make assumptions to investigate a potentially cost-
effective strategy between 6 months and 1 year of trastu-
zumab use. Finally, the model was internally validated
based on the results of the aforementioned RCTs.
A previously published CEA reported that 1 year of
trastuzumab use is not cost effective in Iran [36]; however,
this study had some methodological inconsistencies when
assessed using the Drummond economic evaluation
checklist [37] and also used an inappropriate trastuzumab
cost. The cost of 1 year of trastuzumab use by a 70-kg
woman was estimated at $48,850, which is inconsistent
with the public price of trastuzumab dosage forms (€500
and €1294 for 150 and 440 mg vials, respectively
[€22,992] [38]). Consequently, it was necessary to conduct
a new study using appropriate methods and more reliable
input parameters. For this purpose, we attempted to design
a standard economic evaluation using country-specific
Fig. 4 The impact of life expectancy on the probabilities of being
cost effective among different treatment strategies. Max age threshold
represents the maximum patient age at onset of treatment that, for
those patients, strategy remains optimal at a particular WTP
threshold, WTP willingness-to-pay, GDP gross domestic product
Fig. 5 The impact of price reduction on max-age threshold at WTP
39GDP in Iran. WTP willingness-to-pay, GDP gross domestic
product, max-age maximum age
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information, such as the results of a real-world cost anal-
ysis that exclusively investigated HER2-positive direct
medical costs in Iran [6].
Our results show that the most cost-effective strategy in
the treatment of early HER2-positive BC in Iran is 6
months of trastuzumab as an adjuvant therapy. This strat-
egy remains optimal, even if the price of trastuzumab is
reduced by almost 30% (Online Resource 1). The 1-year
strategy is only cost effective at higher WTP thresholds.
Since, the 9-month strategy was dominated by the 6-month
and 1-year strategies, from an efficiency perspective, the
6-month and 1-year strategies are the two best strategies. If
the 6-month protocol is considered the standard of care,
and doctors continue to adhere to this strategy, Iran can
save €40 million/year compared with a 1-year trastuzumab
strategy. It is worth noting that all these results can vary if
the age of patients at the onset of treatment is changed, and
that these various strategies for trastuzumab use would not
be cost effective in patients older than 59 years of age
(Fig. 4). In other words, in addition to a lower absolute
WTP threshold for expensive drugs in MICs, life expec-
tancy in these countries (e.g. 76.6 years for Iranian women)
is also generally lower than in HICs. These two issues can
affect the results of a CEA in MICs.
We compared our results with the results of model-
based CEAs [10, 39–42] in other countries that used the
same study perspective (healthcare), time horizon (life-
time), and trastuzumab use duration (1 year). Two studies
(in China [39] and Belgium [42]) calculated ICER values
that were lower than those in our study ($8041 and
€10,315, respectively), while four CEAs (in the US
[40, 41], Australia [43], and the UK [10]) estimated higher
ICERs ($39,982, $26,417, $A22,793, and £25,803,
respectively). Regardless of this variation, in all studies,
including our study, ICERs were primarily affected by the
cost of trastuzumab. Despite the methodological similari-
ties between this study and other studies, we cannot easily
compare our results with other CEAs because of differ-
ences in various parameters, such as costs of trastuzumab,
prices for healthcare services, discount rates, background
mortality rates, and sources of estimation of the effec-
tiveness of trastuzumab. On the other hand, a CEA in
Colombia, using a shorter time horizon (20 years), con-
cluded that trastuzumab is not cost effective, even though
trastuzumab was cheaper (US$4,219 versus €22,992) and
advanced-stage treatment (downstream costs) was more
costly (US$52,093 versus €16,926) compared with costs in
Iran [44]. However, comparisons between that study and
our study are difficult, not only because of differences in
time horizon and cost components but also because of
differences in the sources of clinical effectiveness and
utility values that were used. This means that comparisons
between CEAs of trastuzumab, and between MICs, are also
prone to the same problems that arise when comparisons
between CEAs in HICs are performed.
Our study faced four notable limitations. First, we had
to use the results of studies performed in HICs due to
the lack of country-specific health-related quality of life
(HRQoL). In fact, there are no good-quality publications
on HRQoL in Iran. However, this limitation has no
major impact on the overall results since our one-way
sensitivity analysis showed ±30% changes in utility
values caused less than ±8% changes in the estimated
ICER. Second, the HERA trial has recently reported 11
years of median follow-up, and data from this trial could
have been used to update the parameter estimates in our
model [45]. However, the updated estimate of effec-
tiveness of trastuzumab after 11 years was lower than
the effectiveness after 2 years (i.e. an increase in the HR
for DFS from 0.62 to 0.73). However, the results of one-
way sensitivity analysis (Online Resource 2) that any
reduced effectiveness of trastuzumab would not change
the conclusion that the price of trastuzumab must be
reduced significantly in order for it to have any chance
of being cost effective, even for a subgroup of the
patient population (i.e. younger patients). Third, the cost
effectiveness of the 9-month strategy was estimated
based on an assumption of effectiveness due to a lack of
data. Despite its low impact on the overall results, as
demonstrated by sensitivity analysis (Table 4), our CEA
can be updated when the results of the SOLD [33] and/
or SHORT-HER [34] trials become available. Finally,
while it is known that women with hormone receptor-
negative tumors have an increased risk of recurrence and
death, we did not examine the cost effectiveness of
treatment decisions based on hormone receptor status
[46]. This is something that should be examined in the
future.
Table 5 Results of the internal validation
No trastuzumab
(HERA trial versus model)
6 months of trastuzumab
(PHARE trial versus model)
1 year of trastuzumab
(HERA trial versus model)
Overall survival p = 0.489 p = 0.388 p = 0.424
Disease-free survival p = 0.395 p = 0.319 p = 0.267
A. Ansaripour et al.
New drugs launched in MICs do not necessarily have
the same effectiveness or affordability as in HICs. Poli-
cymakers and other primary stakeholders, such as health-
care professionals and patient communities, should focus
on a strategy that will help to create a balance between the
highest attainable level of health and affordability of the
new drug. However, if there is a desire to implement
widely accepted clinical guidelines in MICs, concessions
are unavoidable. There are four approaches that would lead
to recommending 1 year of trastuzumab use in Iran: (1)
price reduction; (2) use of a higher WTP threshold; (3) a
combination of these two methods; and (4) ‘watchful
waiting’ for a generic product. Our results showed that the
first two options, either price reduction (by -30%) [Fig. 3]
or the use of a higher WTP threshold (4 9 GDP), cannot
achieve a new balancing point between population health
and affordability to switch to a longer course of trastuzu-
mab therapy (Online Resource 3). The third option could
be a potential solution; however, due to changes in the
price of trastuzumab and the WTP threshold, the maximum
age threshold for 1 year of trastuzumab use should be re-
estimated. Moreover, the use of a higher WTP would set a
precedent for other treatments. The ‘watchful waiting’
approach can indeed enhance affordability in MICs; how-
ever, this would mean waiting many years before drugs
such as trastuzumab would be reimbursed in MICs. In
many cases, ‘watchful waiting’ would mean a large amount
of health loss. Therefore, a more equitable solution would
involve revamping pharmaceutical pricing systems to make
new drugs more affordable for lower income countries. For
example, a 75% price reduction would be needed to make
1 year of trastuzumab, the strategy recommended in clin-
ical guidelines in HICs, cost effective for all patients
younger than 76.6 years (the average life expectancy) in
Iran (Fig. 5).
Effectiveness and affordability are not the only two
factors to consider when policymakers make reimburse-
ment decisions. Other factors, such as budget impact and
equity analysis, are also important to consider. In fact,
using multicriteria decision analysis (MCDA) that includes
various factors is likely the best way to help policymakers
reach a satisfactory conclusion [47].
5 Conclusions
Most clinical guidelines prepared in HICs have recom-
mended 1 year of trastuzumab use due to the efficacy of the
drug; however, this treatment strategy would not be an
affordable recommendation in MICs due to the lower
absolute value of the WTP threshold and the lower life
expectancy compared with HICs. Our study showed that 6
months of trastuzumab use is the most cost effective option
for the Iranian healthcare setting at a WTP threshold of
3 9 GDP and a maximum age threshold of 59 years.
Policymakers and other stakeholders in MICs must find the
best way to balance population health and affordability of
an expensive intervention.
Data Availability Statement The model developed within this study
is available from the corresponding author upon request. All model
inputs are described in the paper.
Author Contributions AA, CAU, and WKR designed the study, AA
programmed the model and performed the statistical analyses, and
AA and WKR interpreted the results. AA provided a draft of the
manuscript, and WKR and CAU critically reviewed the manuscript.
Compliance with Ethical Standards
Funding All authors declare that they received no financial support
for this study.
Conflict of interest Amir Ansaripour, Carin A. Uyl-de Groot, and
W. Ken Redekop declare that they have no competing interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Ansaripour A, Uyl-de Groot CA, Foroozanfar M, Rahimi-
moghadam S, Redekop WK. Which is more important for doctors
in a middle-income country, a national guideline or the medical
literature? An adherence survey of trastuzumab use for breast
cancer in Iran. J Cancer Policy. 2016;9:8–13.
2. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri
V, D’Amico R. Trastuzumab containing regimens for early breast
cancer. Cochrane Database Syst Rev. 2012;(4):CD006243
3. Pivot X, Romieu G, Debled M, Pierga J, Kerbrat P, Bachelot T,
Lortholary A, Espie M, Fumoleau P, Serin D, Jacquin J, Jouan-
naud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N,
Cany L, Catala S, Khayat D, Pauporte I, Kramar A. 6 months
versus 12 months of adjuvant trastuzumab for patients with
HER2-positive early breast cancer (PHARE): a randomised phase
3 trial. Lancet Oncol. 2013;14:741–8.
4. Goldhirsch A, Gelber RD, Piccart-Gebhart M, de Azambuja E,
Procter M, Suter TM, Jackisch C, Cameron D, Weber HA,
Heinzmann D, Lago LD, McFadden E, Dowsett M, Untch M,
Gianni L, Bell R, Ko¨hne CH, Vindevoghel A, Andersson M,
Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B,
Baselga J. 2 years versus 1 year of adjuvant trastuzumab for
HER2-positive breast cancer (HERA): an open-label, randomised
controlled trial. Lancet. 2013;382:1021–8.
5. CRNN. Guideline for trastuzumab prescription and an eligibil-
ity priority setting for Iranian breast cancer patients. Part 1 (Ul-
timate guideline). First ed. Tehran: Cancer Research National
Network, Iran Ministry of Health; 2012
Cost Effectiveness of Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran
6. Ansaripour A, Zendehdel K, Tadayon N, Sadeghi F, Uyl-de
Groot C, Redekop WK. Use of data-mining to perform a real
world cost analysis of HER2-positive breast cancer in Iran. Value
Health. 2016;19:A355.
7. Vostakolaei FA,BroedersMJM,RostamiN, vanDijck JAAM, Feuth
T, Kiemeney LALM, Verbeek ALM. Age at diagnosis and breast
cancer survival in Iran. Int J Breast Cancer. 2012;2012:517976.
8. Rezaianzadeh A, Heydari ST, Hosseini H, Haghdoost AA, Bar-
ooti E, Lankarani KB. Prevalence of breast cancer in a defined
population of Iran. Iran Red Crescent Med J. 2011;13:647–50.
9. Haghighat S, Akbari ME, Ghaffari S, Yavari P. Standardized
breast cancer mortality rate compared to the general female
population of Iran. Asian Pacific J Cancer Prev. 2012;13:5525–8.
10. Hall P, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron D.
Updated Cost-effectiveness analysis of trastuzumab for early
breast cancer. PharmacoEconomics. 2011;29:415–32.
11. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A,
Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J,
Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley
A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N,
Wist E, Sa´nchez Rovira P, Piccart-Gebhart MJ. 2-year follow-up
of trastuzumab after adjuvant chemotherapy in HER2-positive
breast cancer: a randomised controlled trial. Lancet.
2007;369:29–36.
12. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S,
Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron
D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A,
Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G,
Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R. Treatment
with trastuzumab for 1 year after adjuvant chemotherapy in
patients with HER2-positive early breast cancer: a 4-year follow-
up of a randomised controlled trial. Lancet Oncol.
2011;12:236–44.
13. Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL,
Wolmark N. HER2 and choice of adjuvant chemotherapy for
invasive breast cancer: national surgical adjuvant breast and
bowel project protocol B-15. J Natl Cancer Inst. 2000;92:1991–8.
14. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Har-
irchi I, Najafi M, Ebrahimi M. Breast cancer in iran: an epi-
demiological review. Breast J. 2007;13:383–91.
15. Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R,
Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E,
Wermuth P, Khasanov R, Feng-yi F, Constantin C, Mayordomo
JI, Su C-, Yu S-, Lluch A, Senkus-Konefka E, Price C, Haslbauer
F, Sahui TS, Srimuninnimit V, Colleoni M, Coates AS, Piccart-
Gebhart MJ, Goldhirsch A, the HERA Study Team. Estimating
the magnitude of trastuzumab effects within patient subgroups in
the HERA trial. Ann Oncol. 2008;19:1090–6.
16. Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A,
Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C,
Cameron D, Dowsett M, Barrios CH, Steger G, Huang C,
Andersson M, Inbar M, Lichinitser M, La´ng I, Nitz U, Iwata
H, Thomssen C, Lohrisch C, Suter TM, Ru¨schoff J, Su¨t}o T,
Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS,
Gelber RD. Trastuzumab after adjuvant chemotherapy in
HER2-positive breast cancer. N Engl J Med.
2005;353:1659–72.
17. Tanis E, van de Velde CJH, Bartelink H, van de Vijver MJ, Putter
H, van der Hage JA. Locoregional recurrence after breast-con-
serving therapy remains an independent prognostic factor even
after an event free interval of 10 years in early stage breast
cancer. Eur J Cancer. 2012;48:1751–6.
18. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J,
Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JGM,
Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M,
Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ.
Trastuzumab-associated cardiac adverse effects in the herceptin
adjuvant trial. J Clin Oncol. 2007;25:3859–65.
19. Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall
T, Thomas GN, Iranipour R. Incidence of cardiovascular diseases
in an Iranian population: the Isfahan Cohort Study. Arch Iran
Med J. 2013;16:138–44.
20. National Organization for Civil Registration. Age-specific mor-
tality rate regarding gender in rural and urban areas. 2015. https://
www.sabteahval.ir/Upload/Modules/Contents/asset99/fg93.pdf.
Accessed 10 Jul 2015.
21. Lidgren M, Wilking N, Jonsson B, Rehnberg C. Health related
quality of life in different states of breast cancer. Qual Life Res.
2007;16:1073–81.
22. CalvertMJ, FreemantleN,Cleland JGF. The impact of chronic heart
failure on health-related quality of life data acquired in the baseline
phase of the CARE-HF study. Eur J Heart Fail. 2005;7:243–51.
23. Ansaripour A, Uyl-de Groot CA, Steenhoek A, Redekop WK.
The drug reimbursement decision-making system in Iran. Value
Health Reg Issues. 2014;3:174–81.
24. The Official Gazette of the Islamic Republic of Iran. Healthcare
services tariffs in public and private sectors. 2017. http://www.
rrk.ir/Laws/. Accessed 3 July 2017.
25. WHO. Choosing interventions that are cost-effective. 2015.
http://www.who.int/choice/en/. Accessed 20 Oct 2015.
26. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty
on the cost-effectiveness plane. Health Econ. 1998;7:723–40.
27. Halpern EF, Weinstein MC, Hunink MGM, Gazelle GS. Repre-
senting both first- and second-order uncertainties by Monte Carlo
simulation for groups of patients. Med Decis Making.
2000;20:314–22.
28. CBI. History of exchange rate. 2016. http://www.cbi.ir/
nonRefExRates/nonRefRates_fa.aspx. Accessed 18 Feb 2016.
29. The World Bank. GDP per capita (current US$). 2015. http://data.
worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed 20 Oct
2015.
30. R Core Team (2015). R: a language and environment for statis-
tical computing. R Foundation for Statistical Computing, Vienna,
Austria. http://www.R-project.org/.
31. Barrett A, Roques T, Small M, Smith RD. How much will Her-
ceptin really cost. BMJ. 2006;333(7578):1118–20.
32. Joensuu H, Kellokumpu-Lehtinen P, Bono P, Alanko T, Kataja V,
Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M,
Turpeenniemi-Hujanen T, Jyrkkio¨ S, Flander M, Helle L, Ingal-
suo S, Johansson K, Ja¨a¨skela¨inen A, Pajunen M, Rauhala M,
Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J.
Adjuvant docetaxel or vinorelbine with or without trastuzumab
for breast cancer. N Engl J Med. 2006;354:809–20.
33. US National Institutes of Health. The synergism or long duration
(SOLD) Study. A randomized phase III study comparing trastu-
zumab plus docetaxel (HT) followed by 5-FU, epirubicin, and
cyclophosphamide (FEC) to the same regimen followed by sin-
gle-agent trastuzumab as adjuvant treatments for early breast
cancer. 2015. https://clinicaltrials.gov/ct2/show/NCT00593697.
Accessed 20 June 2016.
34. Guarneri V, Frassoldati A, Bruzzi P, D’Amico R, Belfiglio M,
Molino A, Bertetto O, Cascinu S, Cognetti F, Di Leo A, Pronzato
P, Crino´ L, Agostara B, Conte P. Multicentric, randomized phase
III trial of two different adjuvant chemotherapy regimens plus
three versus twelve months of trastuzumab in patients with
HER2-positive breast cancer (short-HER trial; NCT00629278).
Clin Breast Cancer. 2008;8:453–6.
35. Cancer Research UK. A trial comparing 6 months and 12 months
of trastuzumab (Herceptin) for early breast cancer (PERSE-
PHONE). 2015. http://www.cancerresearchuk.org/about-cancer/
find-a-clinical-trial/a-trial-comparing-6-months-and-12-months-
of-trastuzumab-for-early-breast-cancer. Accessed 20 June 2016.
A. Ansaripour et al.
36. Aboutorabi A, Hadian M, Ghaderi H, Salehi M, Ghiasipour M.
Cost-effectiveness analysis of trastuzumab in the adjuvant
treatment for early breast cancer. Glob J Health Sci.
2015;7:98–106.
37. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance
GW. Methods for the economic evaluation of health care pro-
grammes. 4th ed. New York: Oxford University Press; 2015.
38. SSO. Price of trastuzumab 150 mg and 440 mg vials in Iran.
2016. http://darman.tamin.ir/Forms/DrugStore/DrugLstLocal.
aspx?pagename=hdpDrugLstLocal. Accessed 1 Dec 2016.
39. Chen W, Jiang Z, Shao Z, Sun Q, Shen K. An economic evalu-
ation of adjuvant trastuzumab therapy in HER2-positive early
breast cancer. Value Health. 2009;12:S82–4.
40. Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber
AM. A cost-effectiveness analysis of adjuvant trastuzumab reg-
imens in early HER2/neu—positive breast cancer. J Clin Oncol.
2007;25:634–41.
41. Garrison LP, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA.
Cost-effectiveness analysis of trastuzumab in the adjuvant setting
for treatment of HER2-positive breast cancer. Cancer.
2007;110:489–98.
42. Van Vlaenderen I, Canon JL, Cocquyt V, Jerusalem G, Machiels
JP, Neven P, Nechelput M, Delabaye I, Gyldmark M, Annemans
L. Trastuzumab treatment of early stage breast cancer is cost-
effective from the perspective of the Belgian health care
authorities. Acta Clin Belg. 2009;64:100–12.
43. Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the
adjuvant treatment of early breast cancer: a lifetime model.
Pharmacoeconomics. 2007;25:429.
44. Buendı´a JA, Vallejos C, Picho´n-Rivie`re A. An economic evalu-
ation of trastuzumab as adjuvant treatment of early HER2-posi-
tive breast cancer patients in Colombia. Biome´dica.
2013;33:411–7.
45. Cameron D, Piccart-Gebhart M, Gelber RD, Procter M, Gold-
hirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni
L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones
B, Bell R, Dowsett M, Jackisch C. 11 years’ follow-up of tras-
tuzumab after adjuvant chemotherapy in HER2-positive early
breast cancer: final analysis of the HERceptin Adjuvant (HERA)
trial. Lancet. 2017;389:1195–205.
46. Leung W, Kvizhinadze G, Nair N, Blakely T. Adjuvant trastu-
zumab in HER2-positive early breast cancer by age and hormone
receptor status: a cost-utility analysis. PLOS Med.
2016;13:e1002067.
47. Marsh K, IJzerman M, Thokala P, Baltussen R, Boysen M, Kalo´
Z, Lo¨nngren T, Mussen F, Peacock S, Watkins J, Devlin N.
Multiple criteria decision analysis for health care decision mak-
ing—emerging good practices: report 2 of the ISPOR MCDA
emerging good practices task force. Value Health.
2016;19:125–37.
48. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder
RD, Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch
A, Cardoso F. Patterns of recurrence and outcome according to
breast cancer subtypes in lymph node-negative disease: results
from International Breast Cancer Study Group Trials VIII and IX.
J Clin Oncol. 2013;31:3083–90.
49. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano
SH. Prognosis of women with metastatic breast cancer by HER2
status and trastuzumab treatment: an institutional-based review.
J Clin Oncol. 2009;28:92–8.
50. Niwinska A, Murawska M, Pogoda K. Breast cancer brain
metastases: differences in survival depending on biological sub-
type, RPA RTOG prognostic class and systemic treatment after
whole-brain radiotherapy (WBRT). Ann Oncol. 2010;21:942–8.
51. SSO. Drug list. 2017. http://www.darman.tamin.ir/Forms/Public/
Druglist.aspx?pagename=hdpDrugList. Accessed 15 July 2017.
Cost Effectiveness of Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran
